PRESENCE-MU: New Algorithms to Signal Processing for Speech Enhancement in Adult Cochlear Implant Recipients.

Sponsor
Cochlear (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06100393
Collaborator
(none)
150
2
1
36
75
2.1

Study Details

Study Description

Brief Summary

The purpose of this clinical investigation is to develop pre-processing strategies to enhance speech and reduce noise for CI listeners. The Master Umbrella Clinical Investigation will be comprised of several sub-investigations, which will aim to optimize speech enhancement algorithms, to improve real-world functionality, and to incorporate them efficiently into CI speech processors.

Condition or Disease Intervention/Treatment Phase
  • Device: Investigational Pre-Processing Algorithm
  • Device: Cochlear Limited standard-of-care pre-processing algorithms
N/A

Detailed Description

This is a feasibility, prospective, multi-center, single-subject, repeated-measures clinical investigation in experienced adult cochlear implant users. The Master Umbrella design will enable the execution of a series of sub-investigations in the same user population, with the goal to evaluate a range of speech enhancement pre-processing algorithms in separate sub-investigations. The primary objectives for each sub-investigation will be consistent with the master umbrella investigation, with secondary and exploratory objectives selected based on the algorithm to be investigated. Secondary and exploratory objectives will be described in the sub-investigation documentation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Masking Description:
Order of IMD and comparator is blinded.
Primary Purpose:
Basic Science
Official Title:
A Feasibility, Prospective, Repeated-measures Investigation of Hearing Outcomes With New Pre-processing Speech Enhancement Algorithms Compared to Standard-of-care Algorithms in Adult Cochlear Implant Recipients: a Master Umbrella Investigation
Anticipated Study Start Date :
Oct 31, 2023
Anticipated Primary Completion Date :
Oct 31, 2026
Anticipated Study Completion Date :
Oct 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Other: Investigational pre-processing algorithm/Standard of Care pre-processing algorithm

Device: Investigational Pre-Processing Algorithm
The algorithms act upon the digital audio signal received by the microphones and other sensors to enhance speech and attenuate noise prior to encoding the signal for delivery to a cochlear implant via the specified system.

Device: Cochlear Limited standard-of-care pre-processing algorithms
Automatic Gain Control, SNR-NR, Forward Focus

Outcome Measures

Primary Outcome Measures

  1. Australian Sentence Test in Noise (AuSTIN) [1 day - Immediately post-screening]

    To determine whether the research algorithm provides non-inferior performance to the standard-of-care algorithm for sentences in noise using an adaptive sentence test in noise scores. Scoring: AuSTIN is scored as a Speech Reception Threshold (SRT), which reflects the volume of speech signal (in decibels, dB) relative to the background noise required for the subject to achieve 50% correct. For example, a score of 2dB SRT means the subject requires the speech to be 2dB louder than the background noise in order to correctly identify 50% of the target sentence. Range: -30dB to +30dB. Lower scores reflect a better outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • User of an approved Nucleus cochlear implant.

  • User of the ACE (Advanced Combination Encoder) sound processing strategy.

  • Aged 18 years or older (no upper age limit).

  • Able to score 20% or more at +10 dB SNR or have an adaptive Speech Recognition Threshold (SRT) of 12 dB or less CI alone on a sentence in babble test.*

  • Fluent speaker in the language used to assess speech perception performance, as determined by the investigator.

  • Willing and able to provide written informed consent.

  • ≥3 months post cochlear implant activation

Exclusion Criteria:
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.

  • Additional health factors, known to the investigator, that would prevent or restrict participation in the audiological evaluations.

  • Investigator site personnel directly affiliated with this study and/or the investigator's immediate families; immediate family is defined as a spouse, parent, child, or sibling.

  • Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation.

  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cochlear Melbourne Melbourne Victoria Australia 3002
2 HEARnet Clinical Studies Melbourne Victoria Australia 3053

Sponsors and Collaborators

  • Cochlear

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cochlear
ClinicalTrials.gov Identifier:
NCT06100393
Other Study ID Numbers:
  • AI5842
First Posted:
Oct 25, 2023
Last Update Posted:
Oct 25, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 25, 2023